Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ventyx Biosciences, Inc. (NasdaqGS: VTYX) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Ventyx will receive $14.00 in cash for each share of Ventyx that they own. KSF is seeking to determine whether this consideration and the process that led to i.

Business Wire • Feb 5, 2026

Halper Sadeh LLC Encourages VTYX and SNCY Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights. Shareholders should contact the firm as there may be limited time to enforce your rights.

GlobeNewsWire • Jan 21, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX

NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • Jan 15, 2026

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

NEWTOWN, Pa., Jan. 8, 2026 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Ventyx Biosciences, Inc. ("Ventyx") (NASDAQ: VTYX), resulting from allegations of providing potentially misleading business information to the investing public.

PRNewsWire • Jan 9, 2026

VTYX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Ventyx Biosciences, Inc. is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Ventyx Biosciences, Inc. (NASDAQ: VTYX) to Eli Lilly and Company for $14.00 per share is fair to Ventyx shareholders. Halper Sadeh encourages Ventyx shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Ventyx and it.

Business Wire • Jan 8, 2026

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX)

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - January 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Eli Lilly and Company (NYSE: LLY) for $14.00 per share of common stock in an all-cash transaction (equal to an aggregate equity value of approximately $1.2 billion). The investigation concerns whether the Ventyx Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders.

Newsfile Corp • Jan 8, 2026

Pharma stocks are set to take off this year, says UBS' Michael Yee

Michael Yee, global head of biotech research at UBS, joins CNBC's ‘Squawk on the Street' to explain why he is bullish on biopharma stocks this year, the pharma M&A outlook, and more.

CNBC Television • Jan 8, 2026

Shareholder Alert: The Ademi Firm investigates whether Ventyx Biosciences, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE, Jan. 7, 2026 /PRNewswire/ -- Ademi LLP is investigating Ventyx (NASDAQ: VTYX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Eli Lilly. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

PRNewsWire • Jan 8, 2026

Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal

Eli Lilly will buy Ventyx Biosciences in an all-cash deal worth $1.2 billion, the companies said on Wednesday, marking the Zepbound maker's latest push to expand beyond its blockbuster diabetes and weight-loss drugs.

Reuters • Jan 7, 2026

Eli Lilly Confirms Plan To Buy Ventyx Biosciences In $1.2 Billion Deal

Eli Lilly confirmed its $1.2 billion plan late Wednesday to acquire Ventyx Biosciences. Ventyx stock ran up nearly 40% during regular trades.

Investors Business Daily • Jan 7, 2026